Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: A multicenter phase II pilot study

Haematologica

Volumn 86, Issue 5, 2001, Pages 523-529

  Dazzi, Claudio ^a   Cariello, Anna ^a   Rosti, Giovanni ^a   Tienghi, Amelia ^a   Mouno, Annamaria ^c   Sabbatini, Roberto ^c   Aieta, Michele ^c   Luca Frassineti, Gian ^b   Vertogen, Bernadette ^a   Giovanis, Petros ^a   Marangolo, Maurizio ^a  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^b Ospedale Pierantoni   (Italy)

^c NONE

Author keywords

Cardiotoxicity; High dose chemotherapy; Inflammatory breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLAMMATION; LEUKAPHERESIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; STANDARD; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFLAMMATION; LEUKAPHERESIS; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0035349446     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992; 10:1014-24.
2. Chauvergne J, Durand M, Dilhuydy MH, Hoerni B, Germain T, Lagarde C. Treatment of inflammatory breast cancer. Controlled study of a combination therapy program. Sem Hop 1982; 58:1813-9.
3. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46:2578-81.
4. Maloisel F, Dufour P, Bergerat JP, et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 1990; 65:851-5.
5. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am 1995; 4: 715-34.
6. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997; 40:321-9.
7. Attia-Sobol J, Ferriére JP, Curè H, et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer 1993; 29A:1081-8.
8. + subsets and engraftment kinetics in breast cancer patients. Haematologica 2000; 85:396-402.
9. Hortobagyi GN, Singletary SE, McNesse MD. Treatment of locally advanced and inflammatory breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S, editors. Diseases of the breast. Philadelphia: Lippencott-Raven; 1996. p. 595-8.
10. Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer 1994; 74 (Suppl):466-76.
11. Rouessé J, Friedman S, Sarrazin D, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 1986; 4:1765-71.
12. Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer 1993, 67:594-601.
13. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-9.
14. Adkins D, Brown R, Trinkaus K, et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. J Clin Oncol 1999; 17:2006-14.
15. Ayash LJ, Elias A, Ibrahim J, et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol 1998; 16: 1000-7.
16. Cagnoni PJ, Nieto Y, Shpall EJ, et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol 1998; 16:1661-8.
17. Somlo G, Doroshow JH, Forman SJ, et al. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 1997; 15:2882-93.
18. Garcia-Carbonero R, Hidalgo M, Paz-Ares L, et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol 1997; 15: 3178-84.
19. Moore MP, lhde JK, Crowe JP Jr, Hakes TP, Kinne DW. Inflammatory breast cancer. Arch Surg 1991; 126:304-6.
20. Reynoso EE, Calderon E, Miranda E, et al. GM-CSF mouthwashes to attenuate severe mucositis after high dose chemotherapy and allogeneic bone marrow transplantation (BMT) or autologous peripheral blood stem cell transplantation (APBSCT). Ann Oncol 1994; 5 (Suppl 8):210-1.
21. Ovilla-Martinez R, Rubio ME, Borbolla JR, Glozale-Llaven JE. GM-CSF mouthwashes as treatment for mucositis in BMT patients. Blood 1994; 84:717a.
22. Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F. Epirubicir and doxorubicin comparative metabolism and pharmacokinetics. A cross over study. Cancer Chemother Pharmacol 1988; 21:221-8.
23. Physicians' Desk Reference eds. 52, 1998; 1286-7.
24. Vorobiof DA, Iturralde M, Falkson G. Assessment of ventricular function by radionuclide angiography in patients receiving 4′-epidoxorubicin and mitoxantrone. Cancer Chemother Pharmacol 1985; 15:253-7.
25. Bowers C, Adkins D, Dunphy F, Harrison B, LeMaistre CF, Spitzer G. Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer. Bone Marrow Transplant 1993; 12:525-30.
26. Hortobagyi GN, Frye D, Buzdar U, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989; 63:37-45.
27. Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17:2237-43.
28. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1:329-41.
29. + peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86:390-7.